JP2022546110A5 - - Google Patents
Info
- Publication number
- JP2022546110A5 JP2022546110A5 JP2022513850A JP2022513850A JP2022546110A5 JP 2022546110 A5 JP2022546110 A5 JP 2022546110A5 JP 2022513850 A JP2022513850 A JP 2022513850A JP 2022513850 A JP2022513850 A JP 2022513850A JP 2022546110 A5 JP2022546110 A5 JP 2022546110A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- heterocyclyldiyl
- peg
- group
- aminoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895379P | 2019-09-03 | 2019-09-03 | |
| US62/895,379 | 2019-09-03 | ||
| PCT/US2020/049041 WO2021046112A1 (en) | 2019-09-03 | 2020-09-02 | Aminoquinoline compounds, immunoconjugates, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546110A JP2022546110A (ja) | 2022-11-02 |
| JP2022546110A5 true JP2022546110A5 (enExample) | 2023-08-30 |
Family
ID=72561946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513850A Pending JP2022546110A (ja) | 2019-09-03 | 2020-09-02 | アミノキノリン化合物、免疫複合体、及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220313835A1 (enExample) |
| EP (1) | EP4025254A1 (enExample) |
| JP (1) | JP2022546110A (enExample) |
| CN (1) | CN114630684A (enExample) |
| CA (1) | CA3148694A1 (enExample) |
| WO (1) | WO2021046112A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CA3176626A1 (en) * | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| AU2023396827A1 (en) | 2022-12-13 | 2025-06-19 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| US7410975B2 (en) * | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20070014795A1 (en) | 2004-12-30 | 2007-01-18 | Dhodapkar Madhav V | Compositions and methods for enhanced dendritic cell maturation and function |
| AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| NZ569204A (en) | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
| PT3199552T (pt) | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
-
2020
- 2020-09-02 US US17/637,381 patent/US20220313835A1/en not_active Abandoned
- 2020-09-02 WO PCT/US2020/049041 patent/WO2021046112A1/en not_active Ceased
- 2020-09-02 JP JP2022513850A patent/JP2022546110A/ja active Pending
- 2020-09-02 CN CN202080073294.4A patent/CN114630684A/zh active Pending
- 2020-09-02 CA CA3148694A patent/CA3148694A1/en active Pending
- 2020-09-02 EP EP20775464.9A patent/EP4025254A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022549510A5 (enExample) | ||
| JP2022553702A5 (enExample) | ||
| JP2022537158A5 (enExample) | ||
| JP2023524271A5 (enExample) | ||
| JP2024523453A5 (enExample) | ||
| JP2022554094A5 (enExample) | ||
| JP2023527962A5 (enExample) | ||
| JP2023553421A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JP2022527114A5 (enExample) | ||
| JP2023106627A (ja) | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス | |
| JP2020518669A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| JP2020512270A5 (enExample) | ||
| JP7208136B2 (ja) | Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー | |
| JP2024501453A5 (enExample) | ||
| JP2020530007A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| JP2023552792A5 (enExample) | ||
| JP2023552791A5 (enExample) | ||
| JP2024533356A5 (enExample) | ||
| JP2024511088A5 (enExample) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| JP2022510505A5 (enExample) | ||
| JP2023552790A5 (enExample) | ||
| JP2023011567A (ja) | システイン改変抗体－毒素複合体（ｔｄｃ）の部位特異的結合サイトのスクリーニング |